On August 3 2023, ARTIVION INC ($NYSE:AORT) announced their financial results for the second quarter of FY2023, ending June 30 2023. The company reported total revenue of USD 89.2 million, a year-over-year growth of 11.1%. Net income was -3.4 million, an improvement over the previous year’s figure of -4.3 million.
ARTIVION INC, a leader in the telecommunication and information technology industry, released its Q2 FY2023 earnings results on Thursday for the period ending June 30 of 2023. The company’s stock opened at $17.0 and closed at $16.8, representing a decrease of 1.7% from the previous closing price of 17.1. Overall, the results from ARTIVION INC’s Q2 FY2023 earnings report are promising, with the company’s net income increasing year-over-year and their expenses being reduced. Despite a slight decrease in stock price, investors can remain optimistic about ARTIVION INC’s performance going forward. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Artivion Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Artivion Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Artivion Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Artivion Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
We have detected 3 risk warnings in the income sheet, balance sheet and cash flow statement. With our analysis, investors can understand the risks associated with investing in these companies. GoodWhale’s Risk Rating system flags companies with financial or business problems that could potentially lead to a poor performance of their investments. We have noticed some irregularities in ARTIVION INC‘s income sheet, balance sheet and cash flow statement. This includes changes in receivables, inventory, liabilities, and cash flow which all indicate potential risks. We invite investors to register with us to receive more detailed information about ARTIVION INC and other companies like it that we have analyzed. With this information, investors can make informed decisions about their investments. More…
Risk Rating Analysis
Star Chart Analysis
The company has a strong market presence in Europe and North America. Artivion Inc competes with BICO Group AB, IVF Hartmann Holding AG, and Bioventus Inc. in the global IVF market.
BICO Group AB is a Swedish company that provides healthcare and hygiene products. The company has a market cap of 215.89M as of 2022 and a Return on Equity of 0.14%. BICO Group AB’s products include medical gloves, face masks, and disinfectants. The company’s products are used in hospitals, clinics, and by consumers.
– IVF hartmann Holding AG ($LTS:0QQM)
As of 2022, hartmann Holding AG has a market cap of 268.8M and a Return on Equity of 4.11%. The company is engaged in the production of medical and hygiene products.
Bioventus Inc is a medical device company that focuses on the development and commercialization of products for the orthopedic market. The company has a market cap of 423.63M as of 2022 and a Return on Equity of -5.08%. Bioventus was founded in 2006 and is headquartered in Durham, NC.
Investors are likely to be encouraged by the 11.1% increase in revenue reported by ARTIVION INC for the second quarter of FY2023. Despite a net income of -3.4 million, this figure is an improvement on the same quarter of the previous year, where net income was -4.3 million. The company’s financial performance indicates that it has successfully managed to drive growth despite the challenging market conditions. This could be an attractive opportunity for investors looking for a reliable return on their investments.